A Chimeric Antigen Receptor With Antigen-Independent OX40 Signaling Mediates Potent Antitumor Activity

Scientists engineered a type of CAR-T cells with a costimulatory signal that was activated independently from the tumor antigen to recapitulate physiological stimulation.
[Science Translational Medicine]
Zhang, H., Li, F., Cao, J., Wang, X., Cheng, H., Qi, K., Wang, G., Xu, K., Zheng, J., Fu, Y.-X., & Yang, X. (2021). A chimeric antigen receptor with antigen-independent OX40 signaling mediates potent antitumor activity. Science Translational Medicine, 13(578). https://doi.org/10.1126/scitranslmed.aba7308 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Dynamics of Genome Architecture and Chromatin Function during Human B Cell Differentiation and Neoplastic Transformation

Scientists integrated in situ Hi-C and nine additional omics layers. Beyond conventional active and inactive compartments, they uncovered a highly-dynamic intermediate compartment enriched in poised and polycomb-repressed chromatin.
[Nature Communications]
Vilarrasa-Blasi, R., Soler-Vila, P., Verdaguer-Dot, N., Russiñol, N., Di Stefano, M., Chapaprieta, V., Clot, G., Farabella, I., Cuscó, P., Kulis, M., Agirre, X., Prosper, F., Beekman, R., Beà, S., Colomer, D., Stunnenberg, H. G., Gut, I., Campo, E., Marti-Renom, M. A., & Martin-Subero, J. I. (2021). Dynamics of genome architecture and chromatin function during human B cell differentiation and neoplastic transformation. Nature Communications, 12(1), 651. https://doi.org/10.1038/s41467-020-20849-y Cite
Full Article
Bookmark

No account yet? Register

0
Share

Factors Associated with Outcomes after a Second CD19-Targeted CAR T-Cell Infusion for Refractory B-Cell Malignancies

Researchers analyzed data from 44 patients with elapsed or refractory B-cell malignancies who received CD19-targeted chimeric antigen receptor-engineered on a Phase I/II trial.
[Blood]
Gauthier, J., Bezerra, E. D., Hirayama, A. V., Fiorenza, S., Sheih, A., Chou, C. K., Kimble, E. L., Pender, B. S., Hawkins, R. M., Vakil, A., Phi, T.-D., Steinmetz, R. N., Jamieson, A. W., Bar, M., Cassaday, R. D., Chapuis, A. G., Cowan, A. J., Green, D. J., Kiem, H.-P., … Turtle, C. J. (2021). Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies. Blood, 137(3), 323–335. https://doi.org/10.1182/blood.2020006770 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Recent Updates on Chimeric Antigen Receptor T Cell Therapy for Hepatocellular Carcinoma

The authors summarize current chimeric antigen receptor T cell (CAR-T) therapy targets in the treatment of hepatocellular carcinoma (HCC), discuss current obstacles and possible solutions in the process, and describe potential strategies to improve the efficacy of CAR-T cells for patients with HCC.
[Cancer Gene Therapy]
Guo, J., & Tang, Q. (2021). Recent updates on chimeric antigen receptor T cell therapy for hepatocellular carcinoma. Cancer Gene Therapy, 1–13. https://doi.org/10.1038/s41417-020-00259-4 Cite
Abstract
Bookmark

No account yet? Register

0
Share

FYN–TRAF3IP2 Induces NF-κB Signaling-Driven Peripheral T-Cell Lymphoma

Consistent with a driver oncogenic role, FYN–TRAF3IP2 expression in hematopoietic progenitors induced NF-κB-driven T-cell transformation in mice and cooperated with loss of the Tet2 tumor suppressor in peripheral T-cell lymphoma development.
[Nature Cancer]
FYN – TRAF3IP2 induces NF-κB signaling-driven peripheral T-cell lymphoma | Nature Cancer. (n.d.). Retrieved January 22, 2021, from https://www.nature.com/articles/s43018-020-00161-w Cite
Abstract
Bookmark

No account yet? Register

0
Share

Precision BioSciences Announces FDA Accepts IND for PBCAR19B, a Next-Generation, Stealth Cell, CD19 Allogeneic CAR T Candidate for Non-Hodgkin Lymphoma

Precision BioSciences, Inc. announced that the FDA has accepted the Investigational New Drug application for PBCAR19B, a next-generation, stealth cell, CD19 product candidate for patients with relapsed/refractory Non-Hodgkin Lymphoma.
[Precision BioSciences, Inc. (Globe Newswire, Inc.)]
Press Release
Bookmark

No account yet? Register

0
Share

Histone Methyltransferase WHSC1 Inhibits Colorectal Cancer Cell Apoptosis via Targeting Anti-Apoptotic BCL2

Scientists revealed how WHSC1 regulates tumorigenesis and chemosensitivity of colorectal cancer.
[Cell Death Discovery]
Full Article
Bookmark

No account yet? Register

0
Share

Circulating Tumor DNA Is Detectable in Canine Histiocytic Sarcoma, Oral Malignant Melanoma, and Multicentric Lymphoma

Researchers used droplet digital PCR or PCR for antigen receptor rearrangement, to explore tumor-specific point mutations, copy number alterations, and chromosomal rearrangements in the plasma of cancer-affected dogs. They detected circulating tumor DNA in 21/23 of histiocytic sarcoma, 2/8of oral melanoma, and 12/13 of lymphoma cases.
[Scientific Reports]
Prouteau, A., Denis, J. A., De Fornel, P., Cadieu, E., Derrien, T., Kergal, C., Botherel, N., Ulvé, R., Rault, M., Bouzidi, A., François, R., Dorso, L., Lespagnol, A., Devauchelle, P., Abadie, J., André, C., & Hédan, B. (2021). Circulating tumor DNA is detectable in canine histiocytic sarcoma, oral malignant melanoma, and multicentric lymphoma. Scientific Reports, 11(1), 877. https://doi.org/10.1038/s41598-020-80332-y Cite
Full Article
Bookmark

No account yet? Register

0
Share

CXCR5 CAR-T Cells Simultaneously Target B Cell Non-Hodgkin’s Lymphoma and Tumor-Supportive Follicular T Helper Cells

To target both B cell Non-Hodgkin’s lymphoma and follicular T helper cells in the tumor microenvironment, researchers applied a chimeric antigen receptor that recognized human CXCR5 with high avidity.
[Nature Communications]
Bunse, M., Pfeilschifter, J., Bluhm, J., Zschummel, M., Joedicke, J. J., Wirges, A., Stark, H., Kretschmer, V., Chmielewski, M., Uckert, W., Abken, H., Westermann, J., Rehm, A., & Höpken, U. E. (2021). CXCR5 CAR-T cells simultaneously target B cell non-Hodgkin’s lymphoma and tumor-supportive follicular T helper cells. Nature Communications, 12(1), 240. https://doi.org/10.1038/s41467-020-20488-3 Cite
Full Article
Bookmark

No account yet? Register

0
Share

AMOT Suppresses Tumor Progression via Regulating DNA Damage Response Signaling in Diffuse Large B-Cell Lymphoma

Researchers investigated the expression level and biological function of angiomotin (AMOT) in diffuse large B-cell lymphoma (DLBCL). AMOT expression was significantly reduced in DLBCL biopsy section, and low AMOT expression was associated with poor clinical prognosis.
[Cancer Gene Therapy]
Sang, T., Yang, J., Liu, J., Han, Y., Li, Y., Zhou, X., & Wang, X. (2021). AMOT suppresses tumor progression via regulating DNA damage response signaling in diffuse large B-cell lymphoma. Cancer Gene Therapy, 1–11. https://doi.org/10.1038/s41417-020-00258-5 Cite
Full Article
Bookmark

No account yet? Register

0
Share

ALK Ligand ALKAL2 Potentiates MYCN-Driven Neuroblastoma in the Absence of ALK Mutation

Scientists tested whether anaplastic lymphoma kinase AL2 (ALKAL2) ligand could potentiate neuroblastoma progression in the absence of ALK mutation
[EMBO Journal]
Borenäs, M., Umapathy, G., Lai, W.-Y., Lind, D. E., Witek, B., Guan, J., Mendoza-Garcia, P., Masudi, T., Claeys, A., Chuang, T.-P., El Wakil, A., Arefin, B., Fransson, S., Koster, J., Johansson, M., Gaarder, J., Van den Eynden, J., Hallberg, B., & Palmer, R. H. (2021). ALK ligand ALKAL2 potentiates MYCN-driven neuroblastoma in the absence of ALK mutation. The EMBO Journal, n/a(n/a), e105784. https://doi.org/10.15252/embj.2020105784 Cite
Full ArticleGraphical Abstract
Bookmark

No account yet? Register

0
Share
Share